Recent studies found a newly emergent immune checkpoint molecule, CD276, which serves as a T cell inhibitor to promote tumor proliferation and invasion, rather than CD276 acting as a T cell stimulatory molecule as previously described. The gene discussed is CD276; the disease is neoplasm.